Takeda tees up priority review for storied CMV drug from its $62B Shire buyout

One of the Shire drugs that Takeda spotlighted in its $62 billion takeover is getting a speedy look at the FDA.

The drug, maribavir, is being positioned as the first and only treatment for refractory post-transplant cytomegalovirus infection — after a wild 20-year ride that saw it fail studies and get abandoned while other Big Pharma efforts also crashed.